A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function

Melphalan 200 mg/m(2) is the standard conditioning regimen for patients with multiple myeloma (MM) with normal renal function (NRF) undergoing autologous stem cell transplant (ASCT). In an effort to escalate the dose of melphalan and to improve the efficacy, we designed a dose-escalation study of me...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Abidi, Muneer H., Agarwal, Rishi, Tageja, Nishant, Ayash, Lois, Deol, Abhinav, Al-Kadhimi, Zaid, Abrams, Judith, Cronin, Simon, Ventimiglia, Marie, Lum, Lawrence, Ratanatharathorn, Voravit, Zonder, Jeffrey, Uberti, Joseph
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3786738/
https://ncbi.nlm.nih.gov/pubmed/22892551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2012.08.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados